Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238)
NICE recommends tocilizumab as a possible treatment for some children and young people with systemic juvenile idiopathic arthritis.
NICE does not recommend tocilizumab for children and young people whose disease is improving with methotrexate treatment, or who have not yet been treated with methotrexate.
Children and young people should be able to have tocilizumab if they have tried all of the following drugs but they have not worked: NSAIDs (non-steroidal anti-inflammatory drugs), systemic corticosteroids and methotrexate.
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended tocilizumab because it is clinically effective and it is a cost effective use of NHS resources compared with other treatments currently used in clinical practice.
- None found
This page was last updated: 28 June 2012
- Web format
- Full Guidance (PDF)
- TA238 Tocilizumab ar gyfer arthritis idiopathig systemig ymhlith ieuenctid: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
- Clinical audit tool
- Costing statement
- Electronic audit tool
- Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology commissioning guide
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.